Cancer Symposium for the Practitioner: Introduction to Solid Tumors

Adjei, Alex A.; Rajkumar, S. Vincent; Tefferi, Ayalew
January 2007
Mayo Clinic Proceedings;Jan2007, Vol. 82 Issue 1, p107
Academic Journal
The article discusses the development of treatment for cancer in the U.S. According to the author, most therapeutics have been developed empirically by testing large numbers of chemicals on rodent tumors and on human tumor xenografts. He adds that the effect of these approach have been seen with the solid tumors that had been refractory to systemic chemotherapy.


Related Articles

  • Tumor response to sunitinib malate observed in clear-cell sarcoma. Stacchiotti, S.; Grosso, F.; Negri, T.; Palassini, E.; Morosi, C.; Pilotti, S.; Gronchi, A.; Casali, P. G. // Annals of Oncology;May2010, Vol. 21 Issue 5, p1130 

    The article presents the case of a 46-year-old female patient who was diagnosed with metastatic clear-cell sarcoma (CCS). It states that the tumor is composed of two close lesions that are located to the soft tissues of the left knee. It also notes that the patient was treated with chemotherapy...

  • Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. García, V. Moreno; Cejas, P.; Codesido, M. Blanco; Batlle, J. Feliu; Castro^Carpeño, J.; Belda-Iniesta, C.; Barriuso, J.; Sánchez, J. J.; Larrauri, J.; González-Barón, M.; Casado, E. // International Journal of Colorectal Disease;Jul2009, Vol. 24 Issue 7, p741 

    The purpose of this study was to identify clinical and pathological parameters to improve prediction of disease-free survival (DFS) and overall survival (OS) in patients treated with neoadjuvant chemoradiotherapy for rectal cancer. Between July 1995 and May 2007, 148 patients with primary rectal...

  • Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology. Verhoef, C.; de Wilt, J. H.W.; Verheul, H. M.W. // Current Pharmaceutical Design;Jul2006, Vol. 12 Issue 21, p2623 

    In the past decade, many angiogenesis inhibitors have been developed for clinical use in oncology. Surgeons, radiotherapists as well as medical oncologists have been investigating with much effort and enthusiasm the translation of these agents from the preclinical setting into treatment...

  • Soft-Tissue Sarcomas in Adults. Clark, Matthew A.; Fisher, Cyril; Judson, Ian; Thomas, J. Meirion // New England Journal of Medicine;8/18/2005, Vol. 353 Issue 7, p701 

    Focuses on the pathology and treatment of soft-tissue sarcomas. Risk factors for soft-tissue sarcomas; Incidence of the disease in the U.S. and Great Britain compared with all forms of cancer; Comments on the diagnosis of soft-tissue sarcomas in clinical settings; Discussion of the pathology of...

  • Novel Clinical Trial Designs for Innovative Therapies. Schellens, J. H. M.; Beijnen, J. H. // Clinical Pharmacology & Therapeutics;Feb2009, Vol. 85 Issue 2, p212 

    There is a paradigm shift in oncology from the development of classical intravenously applied cytotoxic anticancer drugs to so-called targeted therapies with molecules that are often administered orally on a chronic daily basis. The dose-limiting toxicities of targeted therapies are frequently...

  • Zoledronic acid and chemotherapy reduce tumour size more effectively. Fricker, Janet // British Journal of Hospital Medicine (17508460);Jan2009, Vol. 70 Issue 1, p10 

    The article features a study conducted by professor Robert Coleman and colleagues on the efficacy of zoledronic acid and chemotherapy in reducing tumour size in Great Britain. Results reveal that the addition of zoledronic acid (Zometa) to standard chemotherapy before breast cancer surgery...

  • Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Burcombe, R. J.; Makris, A.; Richman, P. I.; Daley, F. M.; Noble, S.; Pittam, M.; Wright, D.; Allen, S. A.; Dove, J.; Wilson, G. D. // British Journal of Cancer;1/17/2005, Vol. 92 Issue 1, p147 

    Primary systemic therapy (PST) for operable breast cancer enables the identification of in vivo biological markers that predict response to treatment. A total of 118 patients with T2-4 N0-1 M0 primary breast cancer received six cycles of anthracycline-based PST. Clinical and radiological...

  • A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Hanninen, Mikael; Venner, Peter; North, Scott // Canadian Urological Association Journal;Oct2009, Vol. 3 Issue 5, p369 

    Introduction: Docetaxel chemotherapy prolongs survival in metastatic hormone-refractory prostate cancer (mHRPC), but many patients fail to respond to this therapy and there is potential for serious toxicity. Patients differ in their percent prostate-specific antigen (PSA) decline and rate of PSA...

  • Oncology. DeVita, Vincent T.; Deisseroth, Albert B. // JAMA: Journal of the American Medical Association;6/19/96, Vol. 275 Issue 23, p1833 

    Focuses on advances in oncology. Identification and incorporation of molecular technology into the practice of oncology; Research on microsatellite alterations as potential clonal markers; Clarification of regulatory machinery that determines when cancer cells enter the cell cycle; Modification...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics